ATOMOXETINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H21NO.ClH
Molecular Weight	291.816
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CNCC[C@@H](OC1=C(C)C=CC=C1)C2=CC=CC=C2

InChI

InChIKey=LUCXVPAZUDVVBT-UNTBIKODSA-N

InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C17H21NO
Molecular Weight	255.3547
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21411_strattera_lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/atomoxetine.html

Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter. Most common adverse reactions are: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence, constipation, dry mouth, dizziness, erectile dysfunction, and urinary hesitation. Atomoxetine is a substrate for CYP2D6 and hence concurrent treatment with CYP2D6 inhibitors such as bupropion (Wellbutrin) or fluoxetine (Prozac) is not recommended, as this can lead to significant elevations of plasma atomoxetine levels.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Norepinephrine transporter 191 Target ID: CHEMBL222 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21411_strattera_lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/12431845 \| https://www.ncbi.nlm.nih.gov/pubmed/23933039	Inhibitor 8297	5.0 nM [Ki]
Serotonin transporter 178 Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12431845 \| https://www.ncbi.nlm.nih.gov/pubmed/23933039	Inhibitor 8297	77.0 nM [Ki]
Dopamine transporter 180 Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12431845	Inhibitor 8297	1451.0 nM [Ki]
Glutamate receptor ionotropic, NMDA 2A 2 Target ID: Q00959 Gene ID: 24409.0 Gene Symbol: Grin2a Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20423340	Antagonist 2778	1.58 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Attention deficit hyperactivity disorder 68 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21411_strattera_lbl.pdf	Primary		Approved 8429	STRATTERA Approved Use Attention-Deficit/Hyperactivity Disorder (ADHD) STRATTERA is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of STRATTERA Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see Clinical Studies (14) Launch Date 2002

C_max

Value	Dose	Co-administered	Analyte	Population
414.82 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		ATOMOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2693.29 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		ATOMOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		ATOMOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021411s035lbl.pdf			ATOMOXETINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
180 mg single, oral Overdose Dose: 180 mg Route: oral Route: single Dose: 180 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15732449/	unhealthy, 12 years n = 1 Health Status: unhealthy Condition: mistakenly instead of dextroampheta Age Group: 12 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15732449/	Disc. AE: Tachycardia... AEs leading to discontinuation/dose reduction: Tachycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15732449/
480 mg 1 times / day steady, oral Highest studied dose Dose: 480 mg, 1 times / day Route: oral Route: steady Dose: 480 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, 14 years n = 1 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: 14 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/
2840 mg single, oral Overdose Dose: 2840 mg Route: oral Route: single Dose: 2840 mg Sources: https://pubmed.ncbi.nlm.nih.gov/17307628/	healthy, 17 years n = 1 Health Status: healthy Condition: attempted suicide Age Group: 17 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17307628/	Disc. AE: Sinus tachycardia... AEs leading to discontinuation/dose reduction: Sinus tachycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17307628/
1.2 g single, oral Overdose Dose: 1.2 g Route: oral Route: single Dose: 1.2 g Co-administed with:: oxcarbazepine(36 g) Quetiapine(9 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/15171487/	unknown, 19 years n = 1 Health Status: unknown Age Group: 19 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15171487/	Disc. AE: Depression central nervous system... AEs leading to discontinuation/dose reduction: Depression central nervous system (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15171487/
40 mg 2 times / day steady, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: steady Dose: 40 mg, 2 times / day Co-administed with:: fluoxetine Sources: https://pubmed.ncbi.nlm.nih.gov/27123802/	unhealthy, 26 years n = 1 Health Status: unhealthy Condition: temper outbursts, impulsivity, difficulty paying attention, marital discord Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27123802/	Disc. AE: ST segment elevation myocardial infarction... AEs leading to discontinuation/dose reduction: ST segment elevation myocardial infarction (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/27123802/
1.8 mg/kg 1 times / day steady, oral Highest studied dose Dose: 1.8 mg/kg, 1 times / day Route: oral Route: steady Dose: 1.8 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21422081/	unhealthy, 5 - 6 years n = 44 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: 5 - 6 years Sex: M+F Population Size: 44 Sources: https://pubmed.ncbi.nlm.nih.gov/21422081/	Sources: https://pubmed.ncbi.nlm.nih.gov/21422081/
120 mg 1 times / day steady, oral (max) Studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady Dose: 120 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/	unhealthy, adult n = 45 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: adult Sex: unknown Population Size: 45 Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/	Disc. AE: Nausea, Malaise... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Malaise (1 patient) Anorexia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/
249 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 249 mg, 1 times / day Route: oral Route: steady Dose: 249 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, children n = 40 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: children Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	Other AEs: Drowsiness, Tachycardia... Other AEs: Drowsiness (10 patients) Tachycardia (6 patients) Nausea (3 patients) Hypertension (2 patients) Vomiting (2 patients) Seizure (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/

AEs

AE	Significance	Dose	Population
Tachycardia	1 patient Disc. AE	180 mg single, oral Overdose Dose: 180 mg Route: oral Route: single Dose: 180 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15732449/	unhealthy, 12 years n = 1 Health Status: unhealthy Condition: mistakenly instead of dextroampheta Age Group: 12 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15732449/
Hypertension	1 patient Disc. AE	480 mg 1 times / day steady, oral Highest studied dose Dose: 480 mg, 1 times / day Route: oral Route: steady Dose: 480 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, 14 years n = 1 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: 14 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/
Sinus tachycardia	1 patient Disc. AE	2840 mg single, oral Overdose Dose: 2840 mg Route: oral Route: single Dose: 2840 mg Sources: https://pubmed.ncbi.nlm.nih.gov/17307628/	healthy, 17 years n = 1 Health Status: healthy Condition: attempted suicide Age Group: 17 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17307628/
Depression central nervous system	1 patient Disc. AE	1.2 g single, oral Overdose Dose: 1.2 g Route: oral Route: single Dose: 1.2 g Co-administed with:: oxcarbazepine(36 g) Quetiapine(9 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/15171487/	unknown, 19 years n = 1 Health Status: unknown Age Group: 19 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15171487/
ST segment elevation myocardial infarction	1 patient Disc. AE	40 mg 2 times / day steady, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: steady Dose: 40 mg, 2 times / day Co-administed with:: fluoxetine Sources: https://pubmed.ncbi.nlm.nih.gov/27123802/	unhealthy, 26 years n = 1 Health Status: unhealthy Condition: temper outbursts, impulsivity, difficulty paying attention, marital discord Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27123802/
Anorexia	1 patient Disc. AE	120 mg 1 times / day steady, oral (max) Studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady Dose: 120 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/	unhealthy, adult n = 45 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: adult Sex: unknown Population Size: 45 Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/
Malaise	1 patient Disc. AE	120 mg 1 times / day steady, oral (max) Studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady Dose: 120 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/	unhealthy, adult n = 45 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: adult Sex: unknown Population Size: 45 Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/
Nausea	1 patient Disc. AE	120 mg 1 times / day steady, oral (max) Studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady Dose: 120 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/	unhealthy, adult n = 45 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: adult Sex: unknown Population Size: 45 Sources: https://pubmed.ncbi.nlm.nih.gov/21265936/
Seizure	1 patient	249 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 249 mg, 1 times / day Route: oral Route: steady Dose: 249 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, children n = 40 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: children Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/
Drowsiness	10 patients	249 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 249 mg, 1 times / day Route: oral Route: steady Dose: 249 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, children n = 40 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: children Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/
Hypertension	2 patients	249 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 249 mg, 1 times / day Route: oral Route: steady Dose: 249 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, children n = 40 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: children Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/
Vomiting	2 patients	249 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 249 mg, 1 times / day Route: oral Route: steady Dose: 249 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, children n = 40 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: children Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/
Nausea	3 patients	249 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 249 mg, 1 times / day Route: oral Route: steady Dose: 249 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, children n = 40 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: children Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/
Tachycardia	6 patients	249 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 249 mg, 1 times / day Route: oral Route: steady Dose: 249 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/	unhealthy, children n = 40 Health Status: unhealthy Condition: attention deficit hyperactivity disorder Age Group: children Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/15870137/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781 substrate 1737	inhibitor 1767 inducer 389 substrate 1037	substrate 1217 inhibitor 1852 inducer 97	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524	P-gp 1537 CYP2C19 991 CYP1A2 1054 CYP2A6 543 CYP2B6 664 CYP2E1 667	CYP1A2 701

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 30	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 30	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 30	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 30	no
CYP2D6 1891	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 30	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 30	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 28, 30	no	no (co-administration study) Comment: coadministration with desipramine did not alter the PK of desipramine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 28, 30
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 28, 30	no	no (co-administration study) Comment: coadministration with midazolam increased AUC by 15% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 11, 28, 30

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 8, 11, 22	major	yes (co-administration study) Comment: coadministration with paroxetine or fluoxetine increased atomoxetine steady-state plasma concentrations Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 8, 11, 22
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17963743/	unlikely
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 22.0	weak
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 22.0	weak
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 22.0	weak
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 22.0	weak
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 22.0	weak
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 22.0	weak
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P1.pdf Page: 22.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_pharmr_P1.pdf Page: 15.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:127342	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:127342
ChemicalBook	CB3378328	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3378328
MolPort	MolPort-002-052-062	https://www.molport.com/shop/molecule-link/MolPort-002-052-062
ZINC	ZINC000001842633	http://zinc15.docking.org/substances/ZINC000001842633
eMolecules	1883572	https://www.emolecules.com/cgi-bin/more?vid=1883572

PubMed

Title	Date	PubMed
An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.	2001 Fall	11642475
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.	2001 Nov	11694667
The norepinephrine transporter gene and attention-deficit hyperactivity disorder.	2002 Apr 8	11920844
Drugs under investigation for attention-deficit hyperactivity disorder.	2002 Aug	12211416
Castration increases nisoxetine-evoked norepinephrine levels in vivo within the olfactory bulb of male rats.	2002 Aug 9	12133560
Gateways to clinical trials.	2002 Dec	12616965
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.	2002 Jul	12108801
Identification of the human cytochromes P450 responsible for atomoxetine metabolism.	2002 Mar	11854152
Gateways to clinical trials.	2002 Nov	12616707
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.	2002 Nov	12431845
Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder.	2003	14658930
Cardiovascular effects of atomoxetine in children, adolescents, and adults.	2003	12862507
Updates on attention deficit hyperactivity disorder, child abuse and neglect, and sudden infant death syndrome.	2003 Apr	12640282
Atomoxetine and pregnancy.	2003 Aug	12874488
Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.	2003 Dec	14749146
Atomoxetine (strattera) for ADHD.	2003 Feb 3	12571539
Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.	2003 Jan	12485958
Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog.	2003 Jan	12485957
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.	2003 Mar	12621383
Strattera approved to treat ADHD.	2003 Mar-Apr	12715751
Atomoxetine for attention deficit/hyperactivity disorder.	2003 May	12751480
Atomoxetine for ADHD.	2003 Nov 1	14620603
The use of antidepressants to treat attention deficit hyperactivity disorder in adults.	2003 Sep	14513926
Non-stimulant medications in the treatment of ADHD.	2004	15322961
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD.	2004 Aug	15365896
Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies.	2004 Aug	15363606
Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect.	2004 Aug 2	15225731
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.	2004 Feb	14709944
Atomoxetine treatment of attention-deficit/hyperactivity disorder.	2004 Jan	14742801
Gateways to clinical trials.	2004 Jan-Feb	14988742
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.	2004 Jul	15231966
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.	2004 Jul	15213591
Potential noradrenergic targets for cognitive enhancement in schizophrenia.	2004 May	15115947
New drugs for the treatment of attention-deficit/hyperactivity disorder.	2004 Nov	15571486
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.	2004 Nov 15	15581262
Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder.	2004 Sep	15575418
Gateways to clinical trials.	2004 Sep	15538546
Atomoxetine and nonresponders to stimulants.	2004 Sep	15337674
Atomoxetine and tics in ADHD.	2004 Sep	15322408
Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.	2005 Apr	15526000

Patents

Sample Use Guides

In Vivo Use Guide

Atomoxetine should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day.

Route of Administration: Oral

In Vitro Use Guide

Electrophysiological recordings was performed with the extracellular standard solution at different membrane potentials ranging from -80 mV to +40 mV while the concentration of the agonists (100 uM NMDA/10 uM glycine) and the antagonist (25 uM atomoxetine) were kept constant. The inhibitory effect was clearly voltage-dependent, so that the inhibition was attenuated by depolarization.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:02:50 GMT 2023` Edited by `admin` on `Fri Dec 15 15:02:50 GMT 2023`
Record UNII	57WVB6I2W0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ATOMOXETINE HYDROCHLORIDE

Official Name

English

NSC-759104

Code

English

ATOMOXETINE HCL [VANDF]

Common Name

English

(-)-N-METHYL-3-PHENYL-3-(O-TOLYLOXY)PROPYLAMINE HYDROCHLORIDE

Systematic Name

English

ATOMOXETINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

ATOMOXETINE HCL

Common Name

English

ATOMOXETINE HYDROCHLORIDE [USP-RS]

Common Name

English

ATOMOXETINE HYDROCHLORIDE [JAN]

Common Name

English

LY-139603

Code

English

ATOMOXETINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

ATOMOXETINE (AS HYDROCHLORIDE)

Common Name

English

TOMOXETINE HYDROCHLORIDE

Common Name

English

Atomoxetine hydrochloride [WHO-DD]

Common Name

English

ATOMOXETINE HYDROCHLORIDE [MI]

Common Name

English

STRATTERA

Brand Name

English

ATOMOXETINE HYDROCHLORIDE [MART.]

Common Name

English

ATOMOXETINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

BENZENEPROPANAMINE, N-METHYL-.GAMMA.-(2-METHYLPHENOXY)-, HYDROCHLORIDE, (-)

Common Name

English

ATOMOXETINE HYDROCHLORIDE [USAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

173003